Applications of Azelastine in Industrial Manufacturing

As a direct manufacturer of pharmaceutical-grade Azelastine, we supply this active compound to certified industrial clients in specialized downstream sectors. Each application outlined here reflects the validated large-scale uses of Azelastine in regulated environments, where precise formulation, compliance, and integration protocols are critical for consistent quality and regulatory approval.

1. Prescription Nasal Spray Formulation in Allergic Rhinitis Treatment

Production sites for nasal metered-dose spray products incorporate Azelastine as the core antihistaminic ingredient for seasonal and perennial allergic rhinitis therapies. Facilities must uphold stringent pharmacopoeia standards and ensure homogeneous dispersion within aqueous matrices to meet marketed dosage requirements. Azelastine is introduced at controlled process steps to achieve targeted pharmaceutical strength and dose delivery accuracy in the final nasal spray product, addressing allergic symptoms for patient populations worldwide.

Industry compliance standards

• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur.)
• Japanese Pharmacopoeia (JP)
• Good Manufacturing Practice (GMP; ICH Q7, FDA 21 CFR Part 210/211, EU GMP Annex 1)

Typical usage ratio

• 0.10%–0.15% w/v, precisely adjusted based on target formulation concentration (e.g., 137 mcg/spray) and validation batch scale

Downstream process integration

• Weigh-in and wetting in jacketed blending vessels
• Solution preparation with pH control and preservative addition
• Microfiltration, dosing into pre-sterilized bottles, aseptic filling lines, and tested with in-process controls (content uniformity, spray pattern)

Final product types

• Commercial prescription nasal sprays for allergic rhinitis (e.g., multi-dose pump sprays)
• Single-dose nasal dispensers for hospital and outpatient care

2. Ophthalmic Antiallergic Eye Drops Manufacturing

Eye care formulation facilities utilize Azelastine for the production of sterile antiallergic ophthalmic drops, targeting moderate to severe conjunctival allergic conditions. Accurate ingredient dosing and strict aseptic procedures define this application, with raw material addition guided by stability and solubility studies. The material’s critical point of entry is in buffered solution compounding, ensuring compatibility with sensitive ocular tissues and final filtration prior to sterile packaging.

Industry compliance standards

• Ph. Eur. Monograph 01/2018:1105 (Ophthalmic Preparations)
• USP <771> Ophthalmic Products – Quality Tests
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria
• WHO GMP for Sterile Pharmaceutical Products

Typical usage ratio

• 0.05% w/v, tailored according to finished product dosage guidelines and buffer compatibility results

Downstream process integration

• Dispersion in isotonic phosphate buffer solutions at controlled temperature
• Sequential mixing with viscosity-building agents and stabilizers
• Sterile microfiltration (typically 0.22 micron), filling in pre-sterilized low-density polyethylene bottles or single-use vials under class 100 environments

Final product types

• Over-the-counter and prescription anti-allergy eye drop solutions
• Unit-dose preservative-free ampoules for hospitals

3. Oral Antihistamine Tablet and Capsule Production

Pharmaceutical plants engaged in tablet and capsule manufacturing employ Azelastine as an active moiety in oral solid dosage forms for chronic allergic condition management. Granulation processes require precision to assure consistent API distribution, compressibility, and bioavailability. Line batch records document introduction of the compound at the blending or direct compression stages, with formulation ratios defined by maximum daily dosage regulations and absorption profile targets.

Industry compliance standards

• USP/Ph. Eur. monographs for tablets and capsules
• GMP in Finished Dosage Form (ICH Q10, WHO TRS 986)
• FDA 21 CFR Part 211 (for US production)
• EU Directive 2003/94/EC

Typical usage ratio

• 1–2 mg per capsule or tablet, dosage tailored to regulatory strength requirements and in-process uniformity results

Downstream process integration

• Dry powder blending with diluents and flow agents
• High-shear granulation for controlled-release variants
• Compression or encapsulation, followed by finished product sampling (assay, dissolution, uniformity of dosage units)

Final product types

• Pediatric and adult antiallergic oral tablets
• Hard gelatin capsules for chronic allergy treatment

4. Research-Grade Small Volume Bulk for Clinical Trial Supplies

Specialty contract manufacturing and academic research institutions utilize Azelastine in the provision of controlled batches for clinical trial supply, investigational medicinal product development, and stability testing. All material handling adheres to investigational quality protocols, with particular attention paid to traceability, contamination prevention, and protocol-driven batch compounding. Entry into downstream operations generally occurs in pilot-scale blending facilities or clinical batch suites tailored for non-commercial distribution.

Industry compliance standards

• ICH Q7 (Active Pharmaceutical Ingredients for Clinical Trial Use)
• Good Clinical Practice (GCP) and Good Manufacturing Practice for IMPs (EMA Annex 13)
• US FDA IND submission guidelines
• EU Clinical Trials Regulation (EU CTR 536/2014)

Typical usage ratio

• Variable, strictly protocol-defined based on clinical phase needs (typically 1–5 mg per dose batch), with adjustment for stability and blinding requirements

Downstream process integration

• Research compounding in certified cleanrooms or isolators
• Batch subdivision, blinding, and randomization following clinical trial protocol
• Filling and packaging for investigator site delivery, often under direct sponsor QA oversight

Final product types

• Clinical trial kits for investigational allergy medications
• Reference standard material for regulatory filings and method development